Synergic anticancer effect of Itraconazole combination therapy onBevacizumab-resistant cancer cell

阐明了抗真菌药物伊曲康唑的抗血管生成作用。这种作用是基于与贝伐单抗完全不同的机制。我们还澄清了它是基于对内皮细胞的直接抗增殖作用，而不是基于其他血管生成细胞因子。我们的研究结果表明，该伊曲康唑的作用与mTOR抑制剂相同，毒性低于mTOR抑制剂，并与贝伐单抗协同作用于贝伐单抗耐药的癌细胞。

We clarified antiangiogenetic effect of Itraconazole, one of the antifungus drugs. This effect is based on the mechanism which is quite different from that of Bevacizumab. We also clarified it is based on direct anti-proliferation effect on endothelial cells not based on other angiogenetic cytokines. Our results showed that this Itraconazole’s effect is same as mTOR inhibitor, less toxicity than mTOR inhibitor and synergic effect with Bevacizumab on Bevacizumab resistant cancer cell.